AURORA(SH:600666)2014-07-23 16:00Financial Performance - The company's operating revenue for the first half of 2014 was CNY 585.68 million, a decrease of 6.87% compared to the same period last year[20]. - The net profit attributable to shareholders was CNY 26.12 million, down 25.47% year-on-year[20]. - The basic earnings per share decreased to CNY 0.09, a decline of 18.18% from CNY 0.11 in the previous year[19]. - The total revenue for the first half of 2014 was approximately ¥1,020,000,000, with a year-on-year increase of 6.82% in the Southwest region, while other regions saw a decrease of 26.1%[24]. - Total operating income for the current period is CNY 580,140,643.07, a decrease of 6.97% from CNY 623,678,330.20 in the previous period[182]. - The net profit for the current period is CNY 26,117,371, representing an increase compared to the previous period[77]. - The company reported a total of CNY 35,043,429.75 in net profit for the same period last year[79]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 78.55% to CNY 138.01 million compared to CNY 77.30 million in the same period last year[20]. - The company maintained a stable cash position with cash and cash equivalents at CNY 252,488,039.28, down from CNY 336,302,367.54[63]. - The ending cash and cash equivalents balance was ¥15,185,632.55, down from ¥243,343,923.83, reflecting a decrease of approximately 93.8%[72]. - Cash inflow from operating activities totaled ¥652,060,924.74, slightly down from ¥661,338,916.65, indicating a decrease of about 1.9%[71]. - The company reported a total of CNY 1.37 million in unpaid dividends, up from CNY 0.05 million, indicating a significant increase[169]. Assets and Liabilities - The total assets of the company increased by 16.15% to CNY 2.30 billion from CNY 1.98 billion at the end of the previous year[20]. - The total liabilities of the company were RMB 1,850,716,467.23, compared to RMB 1,553,744,150.93 at the beginning of the year, which is an increase of about 19.1%[60]. - The company's equity attributable to shareholders increased to RMB 451,008,610.24 from RMB 428,953,287.41, showing a growth of approximately 5.2%[61]. - The total amount of guarantees provided by the company, excluding guarantees to subsidiaries, reached CNY 47,656.23 million, which accounts for 105.67% of the company's net assets[44]. - The total amount of long-term borrowings decreased from CNY 286,000,000.00 to CNY 264,000,000.00, a reduction of 7.69%[175]. Operational Efficiency - The gross profit margin for the industrial segment was 40.83%, an increase of 4.02 percentage points year-on-year[22]. - The company reported a decrease in sales expenses by 13.14% to CNY 122.32 million, while management expenses increased by 11.01% to CNY 44.09 million[22]. - The company has advanced production lines for various dosage forms, including imported freeze-drying machines and non-PVC co-extruded soft bags, ensuring high-quality production standards[25]. - The company is focusing on expanding its market presence through new product development and strategic partnerships[123]. - The company plans to enhance its research and development efforts to innovate in the pharmaceutical sector[123]. Shareholder Information - The total number of shareholders at the end of the reporting period was 33,942, with the largest shareholder, Chongqing Taiji Industrial Group Co., Ltd., holding 32.39% of the shares[50]. - The company has committed to a shareholder return plan for the years 2012-2014, ensuring dividends to shareholders[47]. - The company distributed CNY 4,062,048.17 to shareholders during the current period[77]. Regulatory and Compliance - The company has no significant litigation or arbitration matters during the reporting period, indicating a stable operational environment[35]. - The company has not faced any penalties or corrective actions involving its directors, supervisors, or major shareholders during the reporting period[48]. - The company does not have any changes in major accounting policies or estimates for the reporting period[120]. Research and Development - Research and development expenses decreased by 3.52% to CNY 4.51 million compared to CNY 4.67 million in the previous year[22]. - The company has invested ¥4,000,000 in gene engineering interferon ω, with ¥3,000,000 already paid, and the technology is still in the clinical research stage[32]. Inventory Management - The total inventory at the end of the period is 530,825,273.65 CNY, with a decrease in the provision for inventory depreciation to 1,635,303.66 CNY[140]. - Raw materials account for a book value of 279,695,310.97 CNY, with a provision of 204,505.17 CNY[140]. - The inventory of finished goods has a book value of 165,526,599.47 CNY after a provision of 1,430,798.49 CNY[142]. Financial Reporting and Accounting - The financial statements are prepared based on the going concern assumption, ensuring the company's ability to continue operations[87]. - The company adheres to the Chinese Accounting Standards, ensuring the financial reports reflect a true and complete picture of its financial status[88]. - The company utilizes a weighted average method for inventory valuation and assesses net realizable value to determine inventory write-downs[103].